- Home
- GPRK vs AURA Comparison
GPRK vs AURA Comparison
Compare GPRK & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- AURA
- Stock Information
- Founded
- GPRK 2002
- AURA 2007
- Country
- GPRK Colombia
- AURA United States
- Employees
- GPRK N/A
- AURA N/A
- Industry
- GPRK Oil & Gas Production
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- AURA Health Care
- Exchange
- GPRK Nasdaq
- AURA Nasdaq
- Market Cap
- GPRK 335.7M
- AURA 396.8M
- IPO Year
- GPRK N/A
- AURA 2021
- Fundamental
- Price
- GPRK $8.09
- AURA $6.13
- Analyst Decision
- GPRK Buy
- AURA Strong Buy
- Analyst Count
- GPRK 1
- AURA 5
- Target Price
- GPRK $11.00
- AURA $21.80
- AVG Volume (30 Days)
- GPRK 1.7M
- AURA 302.8K
- Earning Date
- GPRK 11-05-2025
- AURA 11-13-2025
- Dividend Yield
- GPRK 7.27%
- AURA N/A
- EPS Growth
- GPRK N/A
- AURA N/A
- EPS
- GPRK 0.81
- AURA N/A
- Revenue
- GPRK $560,354,000.00
- AURA N/A
- Revenue This Year
- GPRK N/A
- AURA N/A
- Revenue Next Year
- GPRK N/A
- AURA N/A
- P/E Ratio
- GPRK $10.04
- AURA N/A
- Revenue Growth
- GPRK N/A
- AURA N/A
- 52 Week Low
- GPRK $5.66
- AURA $4.35
- 52 Week High
- GPRK $11.72
- AURA $11.29
- Technical
- Relative Strength Index (RSI)
- GPRK 67.81
- AURA 50.84
- Support Level
- GPRK $6.52
- AURA $5.62
- Resistance Level
- GPRK $8.27
- AURA $6.60
- Average True Range (ATR)
- GPRK 0.33
- AURA 0.36
- MACD
- GPRK 0.18
- AURA 0.03
- Stochastic Oscillator
- GPRK 92.86
- AURA 54.08
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.